

Curriculum Vitae

Ed Vital

Affiliations

1. NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust
2. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds

Contact Details

Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, LS7 4SA,
Telephone [REDACTED], Fax [REDACTED], email [REDACTED]

General Medical Council registration: 4739885

Qualifications

MB ChB	Manchester University	24/07/00
MRCP(UK)	Royal College Physicians (London)	29/07/04
PhD	University of Leeds	23/04/12

Education

1995-2000 University of Manchester
2009-2012 University of Leeds

Professional Membership

- Royal College of Physicians London
- Medical Protection Society
- British Society for Rheumatology
- British Isles Lupus Activity Group (Chair)

ICH-GCP Training

28 Aug 2019

Current Appointments

- Associate Professor in Autoimmune Connective Tissue Diseases, University of Leeds (2014-)
- Honorary Consultant Rheumatologist, Leeds Teaching Hospitals NHS Trust (2014-)

Previous Appointments

- National Institute of Health Research Clinician Scientist, University of Leeds (2014-2019)
- National Institute of Health Research Clinical Lecturer, University of Leeds (2012 – 2014)
- National Institute of Health Research Doctoral Research Fellow, University of Leeds, (2009 – 2011)
- Specialist Registrar, Rheumatology, Yorkshire Deanery (2005-2012)

Research Grants

- CI, Rituximab Objective Outcome Measures Trial in SLE, Hexal. £375k. 2019 - 2021
- CI, Emerging Leaders Award. Medical Research Foundation, £20k. 2019 - 2020
- CI, Improving the evaluation and implementation of biologic therapies in Systemic Lupus Erythematosus. NIHR. £1m. 2014 - 2019
- CI, Predicting response to rituximab in seronegative rheumatoid arthritis. Roche. £70,000 2015 - 2017
- CI, Understanding Cutaneous Response to Rituximab in Systemic Lupus Erythematosus. Academy of Medical Sciences. £29,072
- CI, Ultrasound for Evaluation of Musculoskeletal Lupus. Lupus UK. £57,832
- Workstream Lead, MASTERPLANS (MRC Stratified Medicine Consortium). £5.1m
- Co-I, Identification of "targets" to prevent scarring outcome in cutaneous Lupus. Lupus UK £36,010
- CI, Prediction of Systemic Lupus Erythematosus in At-Risk individuals using a novel type 1 interferon biomarker, MRC CiC, £70,000

- CI, Immunophenotyping Connective Tissue Disease for Optimal Use of Interferon-Targeted Therapies, £250k, AstraZeneca
- CI, Dissecting the role of interferons in the onset of systemic lupus erythematosus, £25K, LupusUK
- Co-I, Plucked hair follicles as a diagnostic test in lupus alopecia, £25K, LupusUK
- Co-I, MRI Imaging in musculoskeletal SLE, £45k, Glenmark Pharmaceuticals

Other Academic Roles

- Chair, British Isles Lupus Activity Group (National collaborative research group)
- UK representative, EULAR standing committee for Investigative Rheumatology
- Convenor of EULAR TaskForce on Interferon Biomarkers
- Member Versus Arthritis Research Advisory Group for Autoimmune Rheumatic Diseases
- Editorial Board, Rheumatology
- Chair, Data Monitoring Committee, RISAPS (National RCT)
- Chair, British Society for Rheumatology Special Interest Group for SLE
- Chair, Steering Committee, RITUXILUP (Global Lupus Nephritis RCT)
- Advisory Board and consultancy for AstraZeneca, Roche, Sandoz, GSK
- DSMB Member for Aurinia (Global RCT)
- Reviewer for Annals of the Rheumatic Diseases, Rheumatology, Arthritis Research and Therapy, Journal of Rheumatology, Lupus Science and Medicine
- PhD examiner UCL, QMUL, University of Rome "Foro Italico", University of Leeds,
- Peer Review Panel Lupus UK
- Research and Innovation Lead, Chapel Allerton Hospital, Leeds

Prizes and Awards

- 2019** Michael Mason Prize (British Society of Rheumatology)
2018 Medical Research Foundation Emerging Leaders (runner up)
2011 Japanese College of Rheumatology International Scholarship
2009 British Society for Rheumatology Young Investigator of the Year
1995 Holland Curtis Award (Undergraduate scholarship, University of Manchester)

PUBLICATIONS

In revision (preprint server papers)

1. Antonios Psarras, Adewonuola Alase, Agne Antanaviciute, Ian M. Carr, Md Yuzaiful Md Yusof, Miriam Wittmann, Paul Emery, George C. Tsokos, **Edward M. Vital**. Plasmacytoid dendritic cells are functionally exhausted while non-haematopoietic sources of type I interferon dominate human autoimmunity. bioRxiv 502047; doi: <https://doi.org/10.1101/502047>. In revision *Nature Communications*

Original Research papers

1. Yasser M. El-Sherbiny, Md Yuzaiful Md Yusof, Antonios Psarras, Elizabeth M.A. Hensor, Kumba Z. Kabba, Katherine Dutton, Alaa A.A. Mohamed, Dirk Elewaut, Dennis McGonagle, Reuben Tooze, Gina Dooddy, Miriam Wittmann, Paul Emery, **Edward Vital**. B cell tetherin: a flow-cytometric cell-specific assay for response to Type-I interferon predicts clinical features and flares in SLE. doi: 10.1002/art.41187. [Epub ahead of print] *Arthritis and Rheumatology*
2. Yusof MM, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, **Vital EM**. Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus. *Lupus*. 2019 Sep 14;961203319873977. doi: 10.1177/0961203319873977. [Epub ahead of print]
3. Shalhaf M, Alase AA, Berekmeri A, Md Yusof MY, Pistollic J, Goodfield MJ, Edward S, Botchkareva NV, Stacey M, **Vital EM**, Wittmann M. Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature. *Lupus Sci Med*. 2019 Jul 14;6(1):e000328. doi: 10.1136/lupus-2019-000328. eCollection 2019.

4. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5.
5. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, **Vital EM**, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.
6. Stevens MJ, Walker-Bone K, Culliford DJ, Alcacer-Pitarch B, Blake A, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Williams AE, Cherry L. Work participation, mobility and foot symptoms in people with systemic lupus erythematosus: findings of a UK national survey. *J Foot Ankle Res*. 2019 Apr 29;12:26. doi: 10.1186/s13047-019-0335-0. eCollection 2019.
7. Md Yusof MY, **Vital EM**, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S. Predicting severe infection and effects of hypogammaglobulinaemia during therapy with rituximab in rheumatic and musculoskeletal diseases. *Arthritis Rheumatol*. 2019 May 27. doi: 10.1002/art.40937. [Epub ahead of print]
8. Hassan SU, Mahmoud K, **Vital EM**. Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort. *Ann Rheum Dis*. 2019 Apr 25. [Epub ahead of print]
9. Mahmoud K, Zayat AS, Md Yusof MY, Hensor EM, Conaghan PG, Emery P, **Vital EM**. Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. *Rheumatology* 2018 (In press)
10. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA, Wakefield RJ, Conaghan PG, Edwards CJ, Emery P, **Vital EM**. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2018 Sep 27.
11. Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, Zayat AS, Shalhaf M, Alase A, Wittmann M, Emery P, **Vital EM**. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. *Ann Rheum Dis*. 2018 Oct;77(10):1432-1439.
12. El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, Mohamed AAA, McGonagle D, Wittmann M, Emery P, **Vital EM**. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. *Sci Rep*. 2018 Apr 11;8(1):5793.
13. McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. *Rheumatology (Oxford)*. 2018 Mar 1;57(3):470-479.

14. Daniel A, Bagnato G, **Vital E**, Del Galdo F. Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. *BMJ Case Rep.* 2017 Oct 20;2017.
15. Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, **Vital EM**. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. *Ann Rheum Dis.* 2017 Nov;76(11):1829-1836.
16. McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. *Rheumatology (Oxford).* 2017 Jun 1;56(6):1049.
17. Glinatsi D, Bird P, Gandjbakhch F, Haavardsholm EA, Peterfy CG, **Vital EM**, Emery P, Conaghan PG, Østergaard M. Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. *J Rheumatol.* 2017 Nov;44(11):1688-1693.
18. Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, **Vital EM**, Dass S, Emery P. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. *Rheumatology (Oxford).* 2017 Aug 1;56(8):1348-1357.
19. McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, **Vital EM**, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. *Rheumatology (Oxford).* 2017 Jun 1;56(6):1041-1043.
20. Williams AE, Blake A, Cherry L, Alcacer-Pitarch B, Edwards CJ, Hopkinson N, **Vital EMJ**, Teh LS. Patients' experiences of lupus-related foot problems: a qualitative investigation. *Lupus.* 2017 Oct;26(11):1174-1181.
21. Cherry L, Alcacer-Pitarch B, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Blake A, Williams AE. The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey. *Lupus.* 2017 Apr;26(4):410-416
22. Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, **Vital EM**, Westhead DR, Tooze RM, Doody GM. Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. *J Immunol.* 2016 Aug 15;197(4):1447-59.
23. Williams AE, Cherry L, Blake A, Alcacer-Pitarch B, Edwards C, Hopkinson N, **Vital E**, The LS. An Investigation into the Scale and Impact of Self-Reported Foot Problems Associated with Systemic Lupus Erythematosus: A Study Protocol and Survey Questionnaire Development. *Musculoskeletal Care.* 2016 Jun;14(2):110-5.
24. Sellam J, Rivière E, Courties A, Rouzairé PO, Toluoso B, **Vital EM**, Emery P, Ferracioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. *Arthritis Res Ther.* 2016 Dec 13;18(1):294.
25. Cherry L, Alcacer-Pitarch B, Hopkinson N, Teh LS, **Vital EM**, Edwards CJ, Blake A, Williams AE. The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey. *Lupus.* 2016 Sep 29.[Epub ahead of print]
26. Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, **Vital EM**, Westhead DR, Tooze RM, Doody GM. Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. *J Immunol.* 2016 Aug 15;197(4):1447-59.
27. Zayat AS, Md Yusof MY, Wakefield RJ, Conaghan PG, Emery P, **Vital EM**. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology (Oxford).* 2016 Mar;55(3):485-94.

28. Alase AA, El-Sherbiny YM, **Vital EM**, Tobin DJ, Turner NA, Wittmann M. IFN λ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. *J Invest Dermatol*. 2015 Aug 19.
29. Md Yusof MY, **Vital EM**, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. *Ann Rheum Dis*. 2015 Sep;74(9):1734-8.
30. **Vital EM**, Wittmann M, Edward S, Yusof Y, Maclver H, Pease CT, Goodfield M, Emery P. Responses to rituximab suggest B cell-independent inflammation in systemic lupus erythematosus. *Arthritis Rheumatol*. 2015 Jun;67(6):1586-91
31. **Vital EM**, Dass S, Buch MH, Rawstron AC, Emery P. An Extra Dose of Rituximab Improves Clinical Response in Rheumatoid Arthritis Patients with Initial Incomplete B cell Depletion: a Randomised Controlled Trial. E-pub ahead of print, *Annals of the Rheumatic Diseases*
32. **Vital EM** and Das S, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? - non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. E-pub ahead of print, *Annals of the Rheumatic Diseases*
33. Ponchel F, **Vital EM**, Emery P. An immunological biomarker to predict methotrexate response in early RA. *Annals of the Rheumatic Diseases* 2013.
34. Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, **Vital EM**, Emery P. Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. *Ann Rheum Dis*. 2013 Mar;72(3):463-4.
35. Fabris M, Quartuccio L, **Vital EM**, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. *Arthritis Rheum*. 2013 Jan;65(1):88-97.
36. **Vital EM**, Dass S, Emery P. Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. *Rheumatology (Oxford)*. 2012 Jun;51(6):1131-2.
37. Díaz-Lagares C, Croca S, Sangle S, **Vital EM**, Catapano F, Martínez-Berriotxo A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. *Autoimmun Rev*. 2012 Mar;11(5):357-64
38. **Vital EM**, Dass S, Buch MH, Henshaw, K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P. Rituximab responses in systemic lupus Erythematosus explained by B cell biomarkers. *Arthritis Rheum*. 2011 May 25. doi: 10.1002/art.30466. [Epub ahead of print]
39. **Vital EM**, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. *Arthritis Rheum*. 2011 Mar;63(3):603-8.
40. **Vital EM**, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P. Management of non-response to rituximab: predictors and outcome of retreatment. *Arthritis Rheum*. 2010 May;62(5):1273-9.
41. **Vital EM**, Dass S, Buch MH, Rawstron AC, Ponchel F, McGonagle D, Emery P. Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. *Arthritis Rheum*. 2009 Jun;60(6):1867
42. Dass S, **Vital EM**, Rawstron AC, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab in rheumatoid arthritis. *Arthritis Rheum*. 2008 Oct;58(10):2993-9..

43. Dass S, Bowman S, **Vital EM**, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P. Reduction of fatigue in Sjogren's Syndrome with Rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis*. 2008 Nov;67(11):1541-4
44. Dass S, **Vital EM** & Emery P. Development of psoriasis after B cell depletion with rituximab. *Arthritis rheum* 56, 2715-18 (2007).
45. Freeston JE, Conaghan PG, Dass S, **Vital E**, Hensor EM, Stewart SP, Emery P. Does extremity-MRI improve erosion detection in severely damaged joints? *Ann Rheum Dis*, 66, 1538-40 (2007).
46. **Vital EM**, Hutton CW, Hughes PM. Premature osteoarthritis of the knee associated with cartilage hypertrophy and phalangeal dysgenesis. *Skeletal Radiol*. 2005 Aug;34(8):494-7.
47. **Vital EM**, Freeston JE, Dass S, Hensor EMA, Ponchel F, Rawstron AC, Emery P. Concomitant methotrexate or leflunomide in rituximab therapy for rheumatoid arthritis: effects on B cell subsets and clinical responses. *Under review, Rheumatology*

Review Articles

1. Berekméri A, Tiganescu A, Alase AA, **Vital EM**, Stacey M, Wittmann M. Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis and Lupus erythematosus. *Front Immunol*. 2019 Aug 21;10:1931. doi: 10.3389/fimmu.2019.01931. eCollection 2019.
2. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. *Rheumatology (Oxford)*. 2017 Oct 1;56(10):1662-1675.
3. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythematosus. *Curr Opin Rheumatol*. 2017 Sep;29(5):486-492.
4. Pentony P, Duquenne L, Dutton K, Mankia K, Gul H, **Vital E**, Emery P. The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. *Discov Med*. 2017 Nov;24(133):191-200.
5. Romão VC, Vital EM, Fonseca JE, Buch MH. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? *Arthritis Res Ther*. 2017 Oct 24;19(1):239.
6. Mahmoud K, Zayat A, Vital EM. Musculoskeletal Manifestations of SLE. *Under Review, Current Opinion in Rheumatology*.
7. Md Yusof MY, **Vital EM**, Buch MH. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. *Curr Rheumatol Rep*. 2015 Oct;17(10):65.
8. Ponchel F, Burska AN, **Vital EM**. Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic? *Pharmacogenomics*. 2014 Jul;15(10):1275-9.
9. Yusof MY, **Vital EM**, Emery P. Biologics in systemic lupus erythematosus: current options and future perspectives. *Br J Hosp Med (Lond)*. 2014 Aug;75(8):440-7.
10. Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, **Vital E**, Nissim A, Winyard PG, Emery P, Ponchel F. Autoantibodies to posttranslational modifications in rheumatoid arthritis. *Mediators Inflamm*. 2014;2014:492873.
11. Md Yusof My, **Vital EM**, Emery P. B cell targeted therapies in systemic lupus erythematosus and ACNA-associated vasculitis: current progress. *Expert Review Clin Immunol*. 2013
12. **Vital EM**, Kay J, Emery P. Rituximab biosimilars. *Expert Opin Biol Ther*. 2013 Apr 22.
13. Ponchel F, **Vital EM**, Kingsbury SR, El-Sherbiny YM. CD4+ T cell subsets in rheumatoid arthritis. *Int J Clinical Rheumatology*. 2012 Feb;7(1):37-53
14. **Goëb V**, Buch MH, Vital EM, Emery P. Costimulation blockade in rheumatic diseases: where are we? *Curr Opin Rheumatol*. 2009 May;21(3):244-50.
15. **Vital EM**, Emery P. The development of targeted therapies in rheumatoid arthritis. *J Autoimmun*. 2008 Nov;31(3):219-27.

16. **Vital EM**, Emery P. Abatacept in the treatment of rheumatoid arthritis. *Ther Clin Risk Manag*. Vol 2(4):365-75 (2008)
17. Dass S., **Vital EM** & Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. *Expert opin pharmacotherapy* 7, 2559-2570 (2006).
18. Dass S, **Vital.E.**, Emery P. Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. *Future Rheumatol* 1, 293-302 (2006).
19. **Vital, E.M.** & Emery, P. Abatacept. *Drugs Today (Barc)* 42, 87-93 (2006)
20. Mackie SL, **Vital EM**, Ponchel F & Emery P. Co-stimulatory blockade as therapy for rheumatoid arthritis. *Current rheumatology reports* 7, 400-6 (2005).

Editorials

1. Dumitru R, Buch M, **Vital EM**. The Law of the Vital Few: choosing parameters of disease activity in rheumatoid arthritis. *J Rheum (in press)*
2. Aringer M & **Vital EM**. Lots of autoantibodies equals lupus? *Arthri Res Ther*. 2013.
3. **Vital, E.M.** & Emery, P. Advances in the treatment of early rheumatoid arthritis. *Am family physician* 72, 1002, 1004 (2005).

Chapters in edited books

1. Alcacer-Pitarch B, **Vital EM**, Buch MH. Autoimmune Connective Tissue Diseases. In *The foot and ankle in rheumatology*, Oxford 2019
2. Yusof Md, **Vital EM**, Emery P. Rituximab. In *Rheumatology*, Mosby 2019
3. Yusof Md, **Vital EM**, Emery P. Rituximab. In *Rheumatology*, Mosby 2016
4. Freeston JE, **Vital EM**. Ultrasound in Rheumatology. In *Medicine*
5. **Vital EM**. Rituximab. In *Atlas of Rheumatology*, 2013
6. **Vital EM**, Dass S, Emery P. B cell depletion. In *Rheumatology*, Mosby 2013.
7. Dass S, **Vital EM**, Emery P. B cell depletion. In *Rheumatology*, Mosby 2010.
8. **Vital E.M.**, Dass S., Emery P. B Cell Targets in Rheumatoid Arthritis. In *New Therapeutic Targets in Rheumatoid Arthritis*. Birkhauser. (2009)
9. Dass S, **Vital EM**, Emery P Rituximab. In *Rheumatoid Arthritis*, Mosby 2008.
10. **Vital EM**, Emery P. Rheumatic manifestations of malignant haematological conditions. *Reports on the rheumatic diseases* Feb 2007. Arthritis Research Campaign.